<DOC>
	<DOCNO>NCT00943540</DOCNO>
	<brief_summary>The license dose raltegravir 400 mg twice daily without food . Raltegravir metabolize predominantly glucuronidation UGT1A1 . Atazanavir increase plasma concentration raltegravir 400 mg twice daily 72 % due inhibition UGT 1A1 . This suggest combine use atazanavir lower dose frequency raltegravir , daily example , possible . Another reason raltegravir likely applied pharmacodynamic effect relate Cmin AUC expect similar 800mg QD dose compare 400mg BD . Phase III clinical trial evaluate QD dose raltegravir currently ongoing interim result expect publish mid 2009 . A regimen atazanavir raltegravir combination lamivudine emtricitabine may well tolerate effective NNRTI- , ritonavir-sparing regimen could attractive option first second line ( NRTI/NNRTI failure ) treatment regimen .</brief_summary>
	<brief_title>Pharmacokinetic Safety Study Raltegravir Atazanavir Once Daily Dose Regimen HIV-1 Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>HIVinfected document positive HIV antibody test confirm Western Blot . Subject least 18 year age day screen . Subject able willing sign Informed Consent Form prior screen evaluation . HIV1 RNA &lt; 40 copies/mL least 6 month antiretroviral therapy . Subject history previous virological failure document resistance mutation History sensitivity/idiosyncrasy drug chemically related compound excipients , may employ trial . Relevant history current condition might interfere drug absorption , distribution , metabolism excretion . Inability understand nature extent trial procedure require . Pregnant female ( confirm HCG test perform less 3 week first dose ) breastfeed female . Abnormal serum transaminase determine level &gt; 5 time upper limit normal ( see Appendix A normal range clinical laboratory value ) . Concomitant use medication interfere raltegravir atazanavir pharmacokinetics : rifampicin , irinotecan , midazolam , triazolam , ergotamine , dihydroergotamine , cisapride , pimozide , lovastatin , simvastatin , indinavir , proton pump inhibitor , H2 receptor antagonist , St. john 's wort , Ginkgo Biloba , didanosine , tenofovir , efavirenz , nevirapine , antacid , clarithromycin , phenytoin , phenobarbital , carbamazepine . Active hepatobiliary hepatic disease ( include chronic hepatitis B infection ) . Alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>single dose</keyword>
	<keyword>raltegravir</keyword>
	<keyword>Treatment experience</keyword>
</DOC>